COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
9
10
2021
Statut:
ppublish
Résumé
Patients with sarcoidosis may be at higher risk of coronavirus disease-19 (COVID-19) as over 90% of the patients have pulmonary involvement and many are treated with immunosuppressive agents. This review will summarize the current literature regarding sarcoidosis and COVID-19, with a particular focus on susceptibility, clinical outcomes, management, and approach to vaccination. Data about COVID-19 and sarcoidosis include a number of case series and reports, cohort studies, and registries. Literature is not conclusive whether patients with sarcoidosis have increased susceptibility to COVID-19. Patients with moderate to severe impaired pulmonary function may be at increased risk of adverse outcomes and mortality. Whether immunosuppressive medication increases risk of COVID-19 severity or affects vaccination response is not yet clear. Novel approaches, such as telemedicine and home monitoring programs, are promising to ensure continuity of care for patients with sarcoidosis during the COVID-19 pandemic. Current evidence about the risk and clinical outcomes of COVID-19 infection in patient with sarcoidosis, is mainly extrapolated from other immune-mediated diseases. Hence, further research that focuses on the sarcoidosis population is warranted.
Identifiants
pubmed: 34397613
doi: 10.1097/MCP.0000000000000812
pii: 00063198-202109000-00025
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
463-471Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Grunewald J, Grutters JC, Arkema EV, et al. Sarcoidosis. Nat Rev Dis Primers 2019; 5:45.
Spagnolo P, Rossi G, Trisolini R, et al. Pulmonary sarcoidosis. Lancet Respir Med 2018; 6:389–402.
Wiersinga WJ, Rhodes A, Cheng AC, et al. Transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782–793.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020; 80:607–613.
Chatterjee SK, Saha S, Munoz MNM. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci 2020; 7:196.
Broos CE, Poell LHC, Looman CWN, et al. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respir Med 2018; 138S:S31–S37.
Ramstein J, Broos CE, Simpson LJ, et al. IFN-gamma-producing T-Helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-Helper Type 1 cells. Am J Respir Crit Care Med 2016; 193:1281–1291.
Damsky W, Thakral D, Emeagwali N, et al. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med 2018; 379:2540–2546.
Damsky W, Young BD, Sloan B, et al. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatol 2020; 2:106–109.
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021; 384:795–807.
Sweiss NJ, Salloum R, Gandhi S, et al. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS One 2010; 5:e9088-e.
Syed H, Ascoli C, Linssen CF, et al. Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37:87–98.
Baughman RP, Lower EE, Buchanan M, et al. Risk and outcome of Covid-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37:e2020009.
Baughman RP, Lower EE, Gibson K. Pulmonary manifestations of sarcoidosis. Presse Med 2012; 41:e289–e302.
Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health 2020; 65:533–546.
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94:91–95.
Drake TM, Docherty AB, Harrison EM, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An International Multicenter Study. Am J Respir Crit Care Med 2020; 202:1656–1665.
Esposito AJ, Menon AA, Ghosh AJ, et al. Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study. Am J Respir Crit Care Med 2020; 202:1710–1713.
Gallay L, Uzunhan Y, Borie R, et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. Am J Respir Crit Care Med 2021; 203:245–249.
Morgenthau AS, Levin MA, Freeman R, et al. Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS-CoV-2. Lung 2020; 198:771–775.
Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021; 93:1449–1458.
Ungprasert P, Crowson CS, Matteson EL. Sarcoidosis increases risk of hospitalized infection. A Population-based Study. Ann Am Thorac Soc 2017; 14:676–681.
Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70:1914–1920.
Gianfrancesco MA, Hyrich KL, Gossec L. Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. Lancet Rheumatol 2020; 2:e250–e253.
Strangfeld A, Schafer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 80:930–942.
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79:859–866.
Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384:693–704.
Landewe RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020; 79:851–858.
Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases – case series from New York. N Engl J Med 2020; 383:85–88.
Salvarani C, Bajocchi G, Mancuso P, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis 2020; 79:986–988.
Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021; 3:e419–e426.
Mehta P, Porter JC, Chambers RC, et al. B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? Lancet Rheumatol 2020; 2:e589–e590.
Sweiss NJ, Korsten P, Syed HJ, et al. When the game changes: guidance to adjust sarcoidosis management during the coronavirus disease 2019 pandemic. Chest 2020; 158:892–895.
Bénézit F, Le Bot A, Jouneau S, et al. COVID-19 in patient with sarcoidosis receiving long-term hydroxychloroquine treatment, France, 2020. Emerg Infect Dis 2020; 26:2513–2515.
Györfi AH, Kopp M, May M, et al. Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. Ann Rheum Dis 2020.
Jeny F, Lhote R, Lorillon G, et al. Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’. Ann Rheum Dis 2020; annrheumdis-202:218957.
Opoka LM, Wyrostkiewicz D, Winek J, et al. SARS-CoV-2 lung disease in a patient with pulmonary sarcoidosis - case report. Adv Respir Med 2020; 88:620–625.
Padala SA, Medepalli VM, Mohammed A, et al. Management of Immunosuppression during severe COVID-19 infection in a patient with pulmonary and cardiac sarcoidosis. J Clin Rheumatol 2020; 26:229–232.
Yates PA, Newman SA, Oshry LJ, et al. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther Adv Respir Dis 2020; 14:1753466620951053.
Manansala M, Ascoli C, Alburquerque AG, et al. Case Series: COVID-19 in African American patients with sarcoidosis. Front Med 2020; 7:588527.
Panel C-TG. Coronavirus disease 2019 (COVID-19) treatment guidelines. Natl Inst Health 2021.
Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease-19 (COVID-19): A European Respiratory Society living guideline. Eur Respir J 2021; 57:2100048doi: 10.1183/13993003.00048-2021.
doi: 10.1183/13993003.00048-2021
Kouri A, Gupta S, Yadollahi A, et al. Addressing reduced laboratory-based pulmonary function testing during a pandemic. Chest 2020; 158:2502–2510.
Nakshbandi G, Moor CC, Wijsenbeek MS. Home monitoring for patients with ILD and the COVID-19 pandemic. Lancet Respir Med 2020; 8:1172–1174.
Moor CC, Gur-Demirel Y, Wijsenbeek MS. Feasibility of a comprehensive home monitoring program for sarcoidosis. J Pers Med 2019; 9:23doi: 10.3390/jpm9020023.
doi: 10.3390/jpm9020023
Moor CC, Mostard RLM, Grutters JC, et al. Home monitoring in patients with idiopathic pulmonary fibrosis. A randomized controlled trial. Am J Respir Crit Care Med 2020; 202:393–401.
Briand J, Behal H, Chenivesse C, et al. The 1-min sit-to-stand test to detect exercise-induced oxygen desaturation in patients with interstitial lung disease. Ther Adv Respir Dis 2018; 12:1753466618793028.
Kahlmann V, Janssen Bonas M, Moor CC, et al. Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. BMC Pulm Med 2020; 20:271.
Medina M, Babiuch C, Card M, et al. Home monitoring for COVID-19. Cleve Clin J Med 2020.
Annis T, Pleasants S, Hultman G, et al. Rapid implementation of a COVID-19 remote patient monitoring program. J Am Med Inform Assoc 2020; 27:1326–1330.
Silven AV, Petrus AHJ, Villalobos-Quesada M, et al. Telemonitoring for patients with COVID-19: recommendations for design and implementation. J Med Internet Res 2020; 22:e20953.
Grutters LA, Majoor KI, Mattern ESK, et al. Home telemonitoring makes early hospital discharge of COVID-19 patients possible. J Am Med Inform Assoc 2020; 27:1825–1827.
Seyhan EC, Gunluoglu G, Altin S, et al. Results of tetanus vaccination in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:3–10.
Tavana S, Argani H, Gholamin S, et al. Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza Other Respir Viruses 2012; 6:136–141.
Rondaan C, Furer V, Heijstek MW, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open 2019; 5:e001035.
Huang Y, Wang H, Tam WWS. Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis. Curr Med Res Opin 1901; 33:8.
Fischer L, Gerstel PF, Poncet A, et al. Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases –– a longitudinal study. Arthritis Res Ther 2015; 17:151.
Kapetanovic MC, Kristensen LE, Saxne T, et al. Impact of antirheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014; 16:R2.
Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67:937–941.
van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62:75–81.
Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79:39–52.
Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases – version 1. Arthritis Rheumatol 2021; 1–13.
Soy M, Keser G, Atagunduz P, et al. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a nonsystematic review. Clin Rheumatol 2021; 1–13.
Haberman RH, Herati RS, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. medRxiv 2021; annrheumdis-2021-220597. Pre-print.